Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Cardiovascular disease clinical medication guide system and method

A technology of medication guidance and guidance system, applied in the medical field to achieve the effect of reducing safety risks and high accuracy

Pending Publication Date: 2020-04-28
ZHEJIANG DIGENA DIAGNOSTIC TECH CO LTD +2
View PDF2 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In response to the above requirements, the purpose of this patent is to establish a clinical medication guidance system for cardiovascular diseases, combining drug gene detection, drug concentration monitoring technology and existing clinical medication guidelines, to design a reasonable individualized medication plan and detailed information, for Clinicians provide evidence for rational drug use, so as to solve the problem of specific plan formulation in the process of individualized treatment, including the choice of drug type, dosage, medication time and route of administration, so that doctors can quickly and accurately treat patients with medication

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Cardiovascular disease clinical medication guide system and method
  • Cardiovascular disease clinical medication guide system and method
  • Cardiovascular disease clinical medication guide system and method

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0064] Such as Figure 1-2 As shown, it is an intelligent guidance system for cardiovascular drugs according to Embodiment 1 of the present invention, which includes a patient information module, a drug gene detection module, a database module, a preliminary scheme formulation module and a report module, and the realization of the system medication scheme includes the following aspects :

[0065] S101, the patient information module collects and records the basic information of the patient's clinical consultation, including individual basic information (such as gender, age), disease status indicators (such as electrocardiogram, blood pressure, blood lipids), and liver and kidney function indicators (such as liver enzyme levels, urea levels ) Wait;

[0066] S102. The drug gene detection module collects samples such as plasma, and uses methods such as quantitative PCR to detect genetic polymorphism information related to cardiovascular drugs in patients, such as information on ...

Embodiment 3

[0089] Such as Figure 4-5 As shown, it is the cardiovascular drug intelligent guidance system of the second embodiment of the present invention. The system includes a treatment information update module, a drug concentration monitoring module, a database module, a program optimization and adjustment module, and a report module. The realization of the system drug program includes the following aspects Aspects:

[0090] S201. The treatment information update module can collect the patient's initial treatment plan information and record the patient's review results, including disease efficacy status indicators and drug adverse reaction status indicators;

[0091]S202. The drug concentration monitoring module collects plasma and other samples, uses liquid phase or liquid phase mass spectrometry to measure the content of the drug in the patient's body, and calculates the AUC level, peak concentration, trough concentration, half-life and other indicators to obtain the individual's ...

Embodiment 4

[0098] The following is a specific application example of Embodiment 2 of the present invention, and the specific process is:

[0099] Patient A, male, 65 years old, admitted to the hospital due to chest pain, atrial fibrillation, premature ventricular contraction, supraventricular wide QRS tachycardia, atrioventricular block, ventricular tachycardia, has been onset for 48 hours, normal blood pressure, moderate nephritis , normal blood lipids, acute myocardial infarction was preliminarily diagnosed, antiarrhythmic drug therapy was planned for 1 month, and the administration method was orally administered twice a day, 0.5g each time. One week later, the wide QRS tachycardia of patient A was significantly relieved in reexamination, and the reexamination results were imported using the treatment information update module, as shown in Table 3 below:

[0100] Table 3 Basic patient information and drug concentration monitoring results

[0101]

[0102] The drug concentration mon...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a cardiovascular disease clinical medication guide system and method. The system employs the drug gene detection technology, the drug concentration monitoring technology and theexisting clinical medication guidance principle; a reasonable individualized medication guidance scheme is designed, and a basis is provided for reasonable medication of clinicians, so the problem offormulating a specific scheme in the individualized treatment process is solved, including selection of drug types, dosages, medication time and medication ways, and the doctors can quickly and accurately perform medication treatment on patients.

Description

technical field [0001] The invention belongs to the field of medical technology, and relates to a clinical medication guidance system and method for cardiovascular diseases. Background technique [0002] Cardiovascular disease is a serious threat to the health of Chinese people. It has the characteristics of a large patient base, high morbidity, high disability and high mortality. Generally, timely and targeted drug treatment is required to relieve symptoms and overcome complications. According to the "China Cardiovascular Disease Report 2017" data, there are about 290 million patients with cardiovascular diseases in my country, including 13 million strokes, 11 million coronary heart diseases, 4.5 million heart failures, 2 million congenital heart diseases, and high Blood pressure 270 million people. Cardiovascular disease is the primary cause of residents' death due to disease, accounting for more than 40% of the total number of residents' deaths from diseases, which is hig...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): G16H70/40G16H20/10
CPCG16H70/40G16H20/10
Inventor 周洲刘华芬张郁王恺隽刘朝晖曲亮马金飞郭惠民李志凯
Owner ZHEJIANG DIGENA DIAGNOSTIC TECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com